CABALETTA BIO, INC. Operating Lease Right-of-Use Assets
CABALETTA BIO, INC. (CABA) had Operating Lease Right-of-Use Assets of $5.68 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-13
- 2026-06-30: Operating Lease, Right-of-Use Asset $5.68M.
- 2026-03-31: Operating Lease, Right-of-Use Asset $2.45M.
- 2025-12-31: Operating Lease, Right-of-Use Asset $3.43M.
- 2025-09-30: Operating Lease, Right-of-Use Asset $3.60M.
| Period end | Operating Lease, Right-of-Use Asset |
|---|---|
| 2026-06-30 | $5.68M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $2.45M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $3.43M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $3.60M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $4.53M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $5.43M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $6.32M 10-K · filed 2026-03-23 |
| 2024-09-30 | $13.60M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $5.93M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $7.69M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $4.91M 10-K · filed 2025-03-31 |
| 2023-10-01 | $953.00 10-K · filed 2024-03-21 |
| 2023-09-30 | $4.13M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $4.08M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $4.54M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $4.99M 10-K · filed 2024-03-21 |
| 2022-01-01 | $7.56M 10-Q · filed 2023-05-11 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |